APOC3

Across TCGA pan-cancer cohorts, APOC3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated APOC3 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher APOC3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APOC3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LUAD, and COAD are the cancer types where APOC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.888	0.581	<.001	51	view →
LUAD	OS	Median	III,IV	0.211	0.667	.002	37	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	OS	Median	II,III,IV	0.900	1.000	.016	6	view →
UCEC	DFS	Quartile	III,IV	0.208	0.847	.027	4	view →
HNSC	OS	Median	II,III,IV	0.930	0.994	.019	4	view →
PDAC	OS	Quartile	III,IV	0.383	1.000	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

APOC3–CCRCC (DFS)

Open the CCRCC breakdown →